Gwo-Shu Mary Lee

Table S3. HMGCR expression intensity

Figure S1. Inclusion flowchart, participants of the Health Professionals Follow-up Study (1986 to 2020) and Physicians’ Health Study (1982 to 2014) with prostate cancer and tumor tissue on tissue microarrays (TMAs).

Table S2. HMGCR expression intensity

Figure S3. Cumulative-average prediagnostic dietary cholesterol.

Table S4. HMGCR expression intensity (median expression per case across cores) and progression to lethal prostate cancer (metastases/prostate cancer death) among men with primary, nonmetastatic prostate cancer in the HPFS (1986 to 2020) and PHS (1982 to 2014) with known tumor PTEN status.

Figure S4. Western blots after shRNA knockdown of HMGCR, in two replicates.

Figure S2. HMGCR expression by cohort before and after adjustment for batch effects using quantile normalization.

Table S4. HMGCR expression intensity (median expression per case across cores) and progression to lethal prostate cancer (metastases/prostate cancer death) among men with primary, nonmetastatic prostate cancer in the HPFS (1986 to 2020) and PHS (1982 to 2014) with known tumor PTEN status.